Introduction
============

The human body harbors hundreds of trillions of microorganisms ([@ref-15]; [@ref-26]). These microbial communities, comprising of bacteria, fungi, archaea, and viruses, are highly complex. These microbes colonize internal and external surfaces, such as mouth, esophagus, stomach, colon, respiratory tract, genitourinary tract, and skin ([@ref-13]). In particular, the disruption of gut microbiota has been linked to a number of gastrointestinal (GI) diseases ([@ref-10]). With the rapid development of high-throughput sequencing technologies, the metagenomics approach allows one to extensively investigate the human microbiota in its naturally occurring state. These findings will ultimately lead to a better understanding of the gut microbiota in relation to the onset of GI diseases ([@ref-24]).

Gut microbiota was known to play an active role in gut homeostasis for many years. The gut microbial composition and metabolic activity can modify the host's susceptibility to diseases via diverse pathologies. For instance, the disruption of gut microbial communities was implicated with CRC ([@ref-9]) as the colon microbiota promotes CRC by eliciting pathogenic host responses ([@ref-8]). In particular, the alterations in the composition, distribution, and metabolism of colon microbiota were shown to disrupt normal homeostasis and lead to the onset of inflammation, dysplasia, and eventually cancer ([@ref-1]; [@ref-18]). More recently, many specific species whose abundance were positively associated with CRC have been identified. Those included *Streptococcus bovis*, *Helicobacter pylori*, *Bacteroides fragilis*, *Enterococcus faecalis*, *Clostridium septicum*, *Fusobacterium* spp., and *Escherichia coli* ([@ref-5]; [@ref-12]).

However, these earlier works have primarily analyzed the species abundance and diversity differences among communities to reveal the associations between gut microbiota and CRC ([@ref-14]; [@ref-23]). It was only recently, researchers began to study microbes at the functional level. The development of metabolomics has markedly facilitated such endeavors. This is made possible because the microbial abundance change will disrupt microbial enzymes that carry out essential physio-biochemical reactions. Such enzymes, as profiled by metabolomics, thus may predict for human disorders. For examples, in the metabolic disorders, such as IBD or obesity, the changes in gut microbiota cause a state of imbalance in metabolic activity and lead to the diseases ([@ref-7]; [@ref-25]; [@ref-27]).

Identifying such systematic enzymatic changes requires a high resolution analysis of microbial metabolic networks. Two primary methods are available to construct enzymatic networks: the constraint-based method ([@ref-4]) and the topological theory-based method. The constraint-based method requires establishing a series of ecological constraint conditions, which requires iterative approximation of unknown parameters in turn. In contrast, the topological theory-based method constructs the network directly by pulling the annotated metabolic and biochemical reaction pathways from databases and removing redundant information from these pathway data as necessary.

Alternatively, in this paper, we demonstrated an approach to construct association networks by computing the local association coefficients of enzymes involved in biochemical reactions and constructing the enzymatic networks using these statistically significant local associations as edges and nodes. Using such derived enzymatic networks, we studied the differentially presented microbial enzymes and metabolic activities using topological analysis. Applying our approach to a large CRC dataset, we identified that the relative abundance of the enzymatic components of *Bifidobacterium*, *Clostridium*, *Fusobacterium nucleatum*, *Porphyromonas gingivalis*, and *Eubacterium*, were significantly higher in the adenoma and CRC patients, as compared to the healthy controls.

Materials and Methods
=====================

Cohort, fecal samples and metagenomic sequencing
------------------------------------------------

The metagenomic dataset ([@ref-31]) used in this study consists of 156 fecal samples of randomly selected volunteers recruited from the Henri Mondor Hospital (Creteil, France), including 61 healthy people, 42 patients with colorectal adenoma, and 53 CRC patients. The dataset were downloaded from the EBI database, where the detailed data description can be found: <https://www.ebi.ac.uk/ena/data/view/PRJEB6070>.

Estimation of enzyme abundance
------------------------------

Raw metagenomics data were translated to functional enzymes using the Kyoto Encyclopedia of Genes and Genomes Ortholog database and the HMP Unified Metabolic Analysis Network 2 (HUMAnN2) software, which is a pipeline for efficient and accurate profiling of abundance in microbial pathways from a community based on metagenomic or metatranscriptomic sequencing data ([@ref-2]). We computed the difference of relative abundances for 2,400 microbial enzymes involved in biochemical reactions between the CRC patients and the healthy controls. The results were standardized to eliminate potential bias in sequencing batches, and to remove any batch effects in enzyme abundances either specific to CRC patients or healthy controls.

HMP Unified Metabolic Analysis Network 2 uses an in-house script to normalize the abundance of enzymes. The script provides a method called "total sum scaling" (TSS) normalization. The relative abundance is then calculated as follows:$$\documentclass[12pt]{minimal}
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Enzymatic association network construction
------------------------------------------

We performed enzymatic association network construction using the extended local similarity analysis (ELSA) algorithm. ELSA was designed and developed by [@ref-29], which uses a dynamic programming algorithm to effectively discover potential local and time-delayed associations of time-series and cross-sectional data. The dynamic programming algorithm can find all potential global, local and time-delayed associations between two series and identify the association with the highest similarity score as the maximum association between them. We used a false discovery rate *Q*-value cutoff of 0.05 to assess the statistical significance. The resulting enzymatic association networks representing statistically significant associations within the three environments were visualized by the Cytoscape ([@ref-22]) software, in which nodes with blue borders in the three association networks represent enzymes enriched in the healthy controls, while yellow nodes represent enzymes enriched in CRC patients.

The ELSA algorithm has been extensively used in the association network analysis of microbial ecological data with a good performance ([@ref-28]). Studies using ELSA have discovered symbiotic relationships among microbes and relationships between microbes and the environment that could not be identified by conventional correlation methods. For instance, [@ref-21] found dynamic mixed associations between bacteria in lakes by using ELSA. [@ref-16] examined the relationship between bacterial community structure and odor emissions during the degradation of soil and pig carcasses by using ELSA. This algorithm not only finds delayed associations, but also effectively identifies pairwise global associations between for multivariate series data.

Network topological analysis
----------------------------

Several topological measures were used in our network analysis, including the clustering coefficient and the betweenness and closeness centralities. The clustering coefficient is a measure of the degree to which nodes in a graph tend to cluster together. The clustering coefficient of the nodes represents their proximity in the network. An increased clustering coefficient correlates with the higher tightness of the cluster involving the node and its neighbors, hence, the node's importance. This feature of clustering coefficient allows its use for the identification of key enzymes. The clustering coefficient is defined as $$\documentclass[12pt]{minimal}
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The betweenness centrality is a topological measure that refers to the number of times a node acts as a bridge along the shortest path between two other nodes. As the betweenness centrality of a node increases, the frequency with which the node acts as a "mediator" between other nodes also increases, indicating the importance of the node. In an enzymatic association network, a high betweenness centrality indicates that a node plays an important linking role and is likely an important disease-related enzyme.

We also used the closeness centrality measure, which is the inverse of the distance from the node to all other nodes in the network. More important nodes in a network generally have a higher closeness centrality, because they tend to locate close to the center of the network from the geometrical perspective. We identified the shortest paths within the network using the Kruskal's algorithm as implemented in the R package *plyr*.

Statistical analysis
--------------------

We tested for the statistically significant abundance difference of enzymes associated with biochemical reactions of gut microbiota between the healthy controls, and adenoma or CRC patients by the two-tailed Wilcoxon rank-sum test.

Results and discussion
======================

Analysis of disease-associated enzymes
--------------------------------------

We identified 157 differentially abundant enzymes among healthy control, adenoma, and CRC patients. We selected 13 enzymes with differentially node degree among healthy control, adenoma, and CRC patients association network. In [Fig. 1](#fig-1){ref-type="fig"}, we identified 13 enzymes showing statistically significant changes in abundance levels. We conducted a detailed analysis of differential enzymes (IDs and names listed in [Table 1](#table-1){ref-type="table"}) and associated microorganisms. The enzymes K02003 (ABC transport system ATP-binding protein, *P* = 5.22E-04), K06147 (ATP-binding cassette, subfamily B, bacterial, *P* = 9.80E-05), K02025 (Multiple sugar transport system permease protein, *P* = 1.74E-06), K02965 (Small subunit ribosomal protein S19, *P* = 1.17E-04), K02470 (DNA gyrase subunit B, *P* = 3.62E-04), K01624 (Fructose-bisphosphate aldolase, *P* = 2.90E-04), K02878 (Large subunit ribosomal protein L16, *P* = 3.45E-04), K04043 (Molecular chaperone DnaK, *P* = 4.66E-03), K09157 (Uncharacterized protein, *P* = 1.46E-05), K01854 (UDP-galactopyranose mutase (UGM), *P* = 4.31E-06), K03091 (RNA polymerase sporulation-specific sigma factor, *P* = 2.10E-03) were all significantly higher in healthy controls. The enzymes K01667 (Tryptophanase, *P* = 4.57E-04) and K01251 (Adenosylhomocysteinase, *P* = 2.37E-03) were all significantly higher in CRC patients. These difference trends were also observed between adenoma and CRC patients, however, with less significant *P*-values, suggesting that though adenoma is an intermediary stage in the CRC development, the enzymatic levels observed in adenoma patients resemble more the healthy controls' as compared to that of the CRC patients.

![Enzymes with significant differences of relative abundance in healthy people, adenoma patients, and colorectal cancer patients.\
Green bar is the relative abundance of enzymes of healthy people. Orange bar is the relative abundance of enzymes of adenoma patients. Red bar is the relative abundance of enzymes of colorectal cancer patients. \*\*\*represent *P* \< 0.001, \*\*represent *P* \< 0.01, \*represent *P* \< 0.05.](peerj-07-7315-g001){#fig-1}
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###### Enzyme annotations.

![](peerj-07-7315-g002)

  ID       Name of enzyme
  -------- --------------------------------------------------
  K02003   ABC transport system ATP-binding protein
  K06147   ATP-binding cassette, subfamily B, bacterial
  K02025   Multiple sugar transport system permease protein
  K02965   Small subunit ribosomal protein S19
  K02470   DNA gyrase subunit B
  K01624   Fructose-bisphosphate aldolase
  K02878   Large subunit ribosomal protein L16
  K04043   Molecular chaperone DnaK
  K09157   Uncharacterized protein
  K01854   UDP-galactopyranose mutase
  K03091   RNA polymerase sporulation-specific sigma factor
  K01667   Tryptophanase
  K01251   Adenosylhomocysteinase

K02003 is the ABC (ATP binding cassette) transporter, and bacteria genomes encoding this protein showed a higher relative abundance in the healthy environment in comparison to either the adenoma or the colorectal environment. As one of the largest metabolic transport systems in humans, the ABC transporter system mainly transfers nutrients, biosynthetic precursors, trace metals, and vitamins, but it also transports lipids, drugs, primary and secondary metabolites. It plays a major role in biosynthetic pathways. It was noted that low ATP-binding cassette protein subfamily (ABCB1, P-glycoprotein) protein levels may promote colorectal carcinogenesis ([@ref-3]). ABCB1 protein levels were also found to be lower in CRC tissue as compared to well-differentiated tissue ([@ref-11]).

Citing another example, K01854 (UGM, an enzyme that catalyzes chemical reactions) had a higher abundance in healthy samples compared to the other two groups ([Fig. 1](#fig-1){ref-type="fig"}). This enzyme is specifically involved in galactose metabolism, as well as amino sugar and nucleotide sugar metabolism, and it plays a major role in the production of cellular energy and the modification of proteins and glycolipids. In an earlier study, [@ref-19] indicated the importance of galactose metabolism in humans. Galactose can be converted into energy. UGM is one of the main enzymes involved in galactose metabolism. Galactose metabolism is crucial for the health of both neonatal development and adults. Disruption of the production of this enzyme will affect galactose metabolism and even cause transferase-deficiency galactosemia in severe cases. [@ref-6] have shown the presence of galactose metabolism disorders in CRC patients. Based on our metabolic association network, we have shown that the abundance of K01854 is lower in the CRC patients than the healthy controls, in agreement with previous findings.

The main enzymatic active genera of galactose metabolism are *Bacteroides* spp. and *Bifidobacterium* spp. The *Bacteroides* spp. participates in polysaccharide degradation and the *Bifidobacterium* spp. participates in galactose metabolism in the gut. Thus, both of these genera may exert protective effects against developing CRC.

There are also enzymes had significantly higher abundances in cancer patients. The most prominent enzymes of the kind were K01251 (adenosylhomocysteinase) and K01667 (tryptophanase) ([Fig. 1](#fig-1){ref-type="fig"}). Therefore, the microbial species producing adenosylhomocysteinase, an enzyme involved in tryptophan metabolism, may facilitate tumor progression as it presented a significantly higher abundance in cancer patients. By using gas chromatography, [@ref-17] found adenosylhomocysteinase to be a protein marker for CRC ([@ref-30]). Interestingly, our enzymatic association network also showed an enriched abundance of K01667 (tryptophanase) in CRC samples. Tryptophanase is a basic amino acid, and tryptophanase metabolism can help cancer escape immune surveillance. Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-catabolizing enzyme and the main enzyme expressed in malignant inflamed gut. In addition, clinical data have shown that tryptophan metabolism promotes tumor progression ([@ref-20]).

Topological attributes of enzymatic association networks
--------------------------------------------------------

In [Fig. S1](#supp-1){ref-type="supplementary-material"}, we showed the global enzymatic association networks we constructed from the ELSA analysis of the enzymic abundance values. Meanwhile, we exhibited the enzymatic network topological attributes of 13 enzymes in [Table 2](#table-2){ref-type="table"}, including the clustering coefficient, and the closeness and betweenness centralities. As we can see, in the order from healthy, to adenoma and CRC samples, there is a decreasing trend of node degree among the enzymes enriched in healthy controls (nodes with blue circles). Here, the degree of a node refers to the number of neighboring nodes that the node has. Such decreasing trend suggested that these enzymes were highly cooperative in the metabolic processes in health controls ([Fig. S1A](#supp-1){ref-type="supplementary-material"}), while the level of cooperation was reduced in adenoma ([Fig. S1B](#supp-1){ref-type="supplementary-material"}) and further reduced to a minimum level in the CRC environment ([Fig. S1C](#supp-1){ref-type="supplementary-material"}). Notably, a similar decreasing trend was observed in the clustering coefficient ([Table 2](#table-2){ref-type="table"}) of healthy control enriched enzymes, which suggested a gradual loss of importance of these healthy enzymes in a pathogenic CRC gut microbial environment.
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###### Topological attributes of 13 nodes of metabolic association networks in the healthy, adenoma, and colorectal cancer environments.

![](peerj-07-7315-g003)

  ID       Clustering coefficient   Closeness centrality   Betweenness centrality                                                          
  -------- ------------------------ ---------------------- ------------------------ ---------- ---------- ---------- ---------- ---------- ----------
  K09157   7.42E-01                 6.70E-01               4.72E-01                 5.66E-01   4.62E-01   4.14E-01   8.76E-03   4.58E-03   4.62E-03
  K06147   7.79E-01                 7.17E-01               5.49E-01                 6.09E-01   6.10E-01   5.03E-01   3.75E-03   5.71E-03   8.28E-03
  K04043   7.81E-01                 7.33E-01               5.00E-01                 5.72E-01   5.12E-01   4.17E-01   3.98E-03   9.93E-03   1.73E-03
  K03091   5.85E-01                 6.65E-01               7.20E-01                 4.97E-01   5.31E-01   4.95E-01   4.32E-03   3.07E-03   6.63E-03
  K02965   1.00E+00                 7.56E-01               0.00E+00                 4.49E-01   4.38E-01   3.00E-01   0.00E+00   7.65E-05   0.00E+00
  K02878   9.62E-01                 6.98E-01               0.00E+00                 4.61E-01   5.30E-01   3.63E-01   9.23E-06   2.89E-03   2.53E-04
  K02470   7.31E-01                 7.18E-01               6.43E-01                 5.97E-01   5.35E-01   4.70E-01   8.81E-03   3.79E-03   3.20E-03
  K02025   8.17E-01                 6.12E-01               4.83E-01                 6.06E-01   6.31E-01   5.47E-01   4.36E-03   1.03E-02   1.27E-02
  K02003   8.81E-01                 7.67E-01               8.02E-01                 5.37E-01   5.67E-01   4.52E-01   1.20E-03   3.68E-03   7.40E-04
  K01854   8.76E-01                 8.07E-01               6.19E-01                 5.31E-01   5.59E-01   4.45E-01   2.72E-03   1.65E-03   1.84E-03
  K01667   7.33E-01                 8.67E-01               5.16E-01                 4.72E-01   3.65E-01   4.06E-01   2.82E-04   5.77E-05   3.82E-03
  K01624   9.82E-01                 7.93E-01               7.33E-01                 5.02E-01   5.15E-01   3.85E-01   2.55E-05   1.82E-03   7.60E-04
  K01251   0.00E+00                 0.00E+00               5.90E-01                 0.00E+00   4.38E-01   4.03E-01   0.00E+00   3.69E-04   2.32E-03

**Note:**

The data range in the table is between (0, 1).

The enzyme K02003, an ABC (ATP binding cassette) transporter, had the highest clustering coefficients in the healthy enzymatic network. This ABC transporter was also identified as significantly more abundant in healthy samples by abundance level (see [Fig. 1](#fig-1){ref-type="fig"}). Both results consistently suggested its status as a signature enzyme species for the healthy gut microbial environment. Similarly, the clustering coefficient of enzyme K02965 (small subunit ribosomal protein S19) was one in the healthy network; however, the coefficient was zero in the CRC network, also suggesting that the enzyme has an important biochemical role in the healthy people, which was no longer found in cancer patients.

In contrast, for the enzymes enriched in the CRC patients, they showed an increasing connectivity from healthy, to adenoma and CRC enzymatic networks. Several such enzymes were uniquely presented in the CRC network. For instance, the K01251 enzyme (Adenosylhomocysteinase), which is a highly connected node in the CRC and adenoma network, however, did not show up in the healthy network at all ([Fig. 1](#fig-1){ref-type="fig"}), suggesting its functional role in the early stage of tumorigenesis. We also found that the betweenness centrality of K01251 was higher in the CRC environment, and zero in the healthy controls (see [Table 2](#table-2){ref-type="table"}). These results suggest that K01251 may play a pathogenic role in intestinal flora metabolism causing its enrichment in the CRC patients.

Conclusion
==========

We analyzed a large human gut metagenomics dataset by using the HUMAnN2 tool to estimate the relative abundances of microbially produced enzymes in the healthy control, adenoma and CRC patient samples, respectively. We identified differentially abundant enzymes among these healthy, adenoma, and CRC patient groups. We constructed enzymatic association networks representing the healthy, adenoma, and CRC microbial environments using the ELSA algorithm, and analyzed the topological attributes of the resulting networks.

The new enzymatic network analysis approach we took in this study addressed the issue in previous studies that the enzymatic association networks were constructed only for individual metabolic pathways involving a limited number of microorganisms. We were able to globally integrated thousands of enzymes and hundreds of metabolic substrates carrying out biochemical reactions. These microbial enzymatic networks represent the set of essential relationships between enzymes of microbial origin. These relationships were indicators of underlying biochemical reactions and production of metabolites. Among the methods available, only this systematic network-based study can reveal these relationships between microbial communities and their host in high resolution.

The innovative point of our network construction is to use an extensively tested and validated metric---local similarity score for building edges in the network. We know various noises and biases are associated with large-scale network construction, which incur challenges in subsequent topological analysis. Also, many constructed enzymatic networks are not specific simply because of the presence of irrelevant metabolites. The use of an accurate and robust association metrics helped us in truthfully representing these metabolic interactions.

Moreover, the topological attributes of the enzymatic network can carry important information of underlying dynamics between the enzymes and the tumorigenesis process. For example, the clustering coefficient is a positive indicator of an enzyme's cooperativity with other enzymes. By systematically constructing the networks using the ELSA algorithm and data-mining in node degree, clustering coefficient, betweenness and closeness centralities of the enzymatic network under different cancer stages, we were able to identify signature enzymic species as well as the local shift in network structure of cooperating enzymes as potential cancer risk markers, which merit further research.

Supplemental Information
========================

10.7717/peerj.7315/supp-1

###### Metabolic association network constructed using samples from healthy people, adenoma patients, and colorectal cancer patients.

\(A\) Metabolic association network of healthy people. (B) Metabolic association network of adenoma patient. (C) Metabolic association network of colorectal cancer patient. In these three networks, the nodes with blue circles represent enzymes enriched in the healthy people, and the nodes with yellow represent enzymes enriched in the colorectal cancer patients, e.g K01251 (adenosylhomocysteinase) was enriched in the adenoma and colorectal cancer samples, but absented in the healthy samples. This enzyme is a biomarker for colorectal cancer.

###### 

Click here for additional data file.
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